![](/wp-content/uploads/2018/10/A8jenTDiS2ycBK4twFh8.png)
$599
Xeris completes Ph3 for stable glucagon
Xeris Pharmaceuticals has announced the completion of two Ph3 clinical trials (adults and pediatrics) and one human factors study for its stable glucagon (no reconstitution required). According to the press release, the company anticipates to submit an NDA filing by the end of Q2 ’18.